Open AccessOld tools revisited give hope – new treatment option for families with a history of severe FNAIT complications
Author(s) -
Tiller Heidi,
Fedorcsak Peter,
Skogen Bjørn R.
Publication year - 2016
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.12842
Subject(s) - neonatal alloimmune thrombocytopenia , medicine , pregnancy , obstetrics , miscarriage , fetus , genetics , biology
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is defined as fetal and neonatal thrombocytopenia caused by maternal alloantibodies directed against fetal platelets due to incompatibility between fetal and maternal platelet antigens (HPAs). The majority of FNAIT cases are caused by anti-HPA-1a antibodies (1). FNAIT is the most common cause of intracranial hemorrhage (ICH) in otherwise healthy term newborns, affecting 1:12,500 - 1:25,000.The clinical outcome of FNAIT-related ICH is typically poor, and the risk of recurrence in subsequent pregnancies is high (2;3). FNAIT is also associated with increased risk of miscarriage, low birth weight, and stillbirth (1;4).. This article is protected by copyright. All rights reserved.